New data hub will accelerate development and adoption of human-based New Approach Methodologies The NYU Langone-Sage ...

Shares of Ferrari (RACE 1.28%) have hit a rough patch. The stock is down significantly from its 52-week high and has fallen ...

Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.

Connecticut's best player, Sarah Strong, is a force on the court and a mystery off it. And, that's the way she wants it.

Icotyde is backed by data from the Phase 3 ICONIC program which, among other advantages, showed significant superiority over Bristol Myers Squibb’s Sotyktu.

France’s higher education landscape provides international students with opportunities to experience diverse academic ...

Representatives from the Michigan Department of Health and Human Services on Tuesday met with the Senate appropriations ...

Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the lucrative psoriasis market with a new approval for a much-anticipate | The ...

MEDINA, Ohio — County commissioners on Tuesday assured a local arts group that it will have a formal role in the county’s ...

For the past 25 years, Strobert has been one of the companies operating in that space between trees and people in Wilmington.

Calbright College, the state’s free online community college, is growing rapidly. Newsom proposes tripling its annual budget.

FDA authorization covers moderate-to-severe plaque psoriasis in adults and patients aged ≥12 years, expanding systemic options for adolescents. Icotrokinra is characterized as a first-in-class ...